Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
glycopyrronium + neostigmine
- Development stage
- Phase 3
- Lead developer
- Slayback Pharma
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
A combination of neostigmine, an acetylcholinesterase inhibitor, and glycopyrronium (also known as glycopyrrolate), a muscarinic antagonist. This combination is primarily indicated for the reversal of residual neuromuscular blockade induced by non-depolarizing neuromuscular blocking agents (NMBAs) following surgery under general anesthesia. Neostigmine works by inhibiting the enzyme acetylcholinesterase, thereby increasing the concentration of acetylcholine at the neuromuscular junction to compete with and displace NMBAs. Glycopyrronium is co-administered to mitigate the systemic muscarinic effects of neostigmine, such as bradycardia, bronchoconstriction, and excessive salivation. Clinical trials, such as those conducted by The Third Xiangya Hospital of Central South University, evaluate this combination against the traditional neostigmine-atropine pairing to assess its impact on perioperative heart rate stability.
- Brand names
- Robinul-Neostigmine
- Other names
- glycopyrrolate + neostigmineneostigmine methylsulfate + glycopyrronium bromideneostigmine + glycopyrronium
02
Targets
AcetylcholinesteraseM1 (Muscarinic acetylcholine receptor M1)
Beyond the preview
Go deeper on glycopyrronium + neostigmine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on glycopyrronium + neostigmine.